Some ER -
positive tumors respond to AI therapy, and some do not.
Not exact matches
«First - line immunotherapy treatment can improve survival for subset of lung cancer patients: Results of phase III global clinical trial show that 75 percent of stage IV lung cancer patients with both complex
tumor mutations and PDL - 1
positive status
respond to nivolumab.»
The authors noted that an important question raised by this study is whether HPV -
positive and HPV - negative
tumors will
respond differently to targeted therapies.
The goal is to develop personalized molecular tests that can predict how ER
positive tumors will
respond to various therapies.
Breast
tumors that are HER2
positive — meaning that they have high levels of a protein called HER2 — often
respond to targeted medications, sometimes known as «smart bombs,» like Herceptin.
Well, most breast
tumors are estrogen receptor
positive, meaning they
respond to estrogen; estrogen makes them grow.